Biocytogen breaks through with its antibody platform, attracting partnerships from global pharmaceutical companies.
Recently, there has been continuous activity in the domestic innovative antibody field, with the commercial value of platform-based Biotechs rapidly emerging. Recently, Biocytogen announced a strategic collaboration with the cutting-edge cell therapy company Moonlight Bio, Inc. This is already the second major licensing deal it has secured within just three months of 2026, demonstrating the ongoing release of its platform value and attracting significant industry attention.
Core of the Collaboration: Joining Forces to Tackle Refractory Cancers, Unlocking Platform Value
According to this strategic collaboration agreement, Biocytogen will leverage its core strengths to provide fully human antibody molecules against therapeutic targets for Moonlight Bio. Moonlight Bio will focus on the preclinical development of related cell therapies. Together, they aim to develop next-generation cell therapies to address various highly challenging refractory cancers, filling a gap in clinical treatment.
As an innovation-driven preclinical CRO and biotechnology company, Biocytogen has a very clear positioning—to become a global source of new drugs. Centered on its self-developed gene-editing technology, the company has built a dual-engine platform comprising a "Fully Human Antibody Library + Humanized Target Mouse Library." Through a systematic and engineered R&D model, it systematically accelerates the global drug development process.
350+ Collaborations as Endorsement: "1000 Mice 10,000 Antibodies" Plan Gains Momentum
As of December 31, 2025, Biocytogen has cumulatively signed over 350 drug collaboration development, licensing, and transfer agreements. Its client portfolio is impressive, covering many global pharmaceutical giants such as Merck KGaA, Gilead, Johnson & Johnson, BeiGene, and Hansoh Pharma. The core confidence enabling its continued recognition by multinational giants lies in its self-developed RenMice fully human antibody platform.
Relying on this platform, Biocytogen launched the industry-renowned "1000 Mice 10,000 Antibodies" plan in 2020, aiming to develop antibodies at scale for over 1,000 potentially druggable targets. It has now established a library of over 1 million fully human antibody sequences, achieving a leap from "finding targets one by one" to "building pipelines in batches." This platform-based, replicable R&D model is precisely the core capability most valued by multinational pharmaceutical companies today.
Two Major Deals in 3 Months: Commercial Value Accelerates Realization
Entering 2026, Biocytogen's business development (BD) pace has noticeably accelerated, with commercial value continuously materializing:
On January 9, the company entered into an option and license agreement with Acepodia to conduct systematic evaluation around bispecific antibody-drug conjugates (BsADCs), further advancing the development of next-generation dual-payload ADCs (BsAD2Cs). According to the agreement, Acepodia obtained global exclusive license options for two BsADC projects, while Biocytogen can receive upfront payments, exercise fees, development and regulatory milestones, commercialization milestones, and sales royalties.
Notably, this collaboration with Acepodia is not starting from scratch but is a deep continuation of their previous joint development partnership—from the early screening and evaluation of bispecific antibody and ADC projects to now advancing next-generation molecular design. Biocytogen continues to empower its partners with its platform, realizing a robust business model of "technology output + value sharing."
Industry Perspective: Platform-based Biotechs Become Core Force in Industry Transformation
Biocytogen's intensive licensing and collaborations are not accidental BD moves but the inevitable result of its platform-based business model's value realization. Currently, innovative drug R&D faces pain points of high cost, long cycles, and significant risks. Multinational pharmaceutical companies increasingly prefer to collaborate with Biotechs possessing underlying technology platforms and scalable pipeline output capabilities to achieve complementary advantages and reduce R&D risks.
With its complete closed-loop of "mouse models + antibody library + scaled development," Biocytogen can provide global pharmaceutical companies with "ready-to-use" high-quality molecules and jointly advance the development of cutting-edge therapies, occupying a key position in the industry's division of labor. In the future, as more collaborative projects advance to clinical stages, its platform value is expected to further amplify, securing a more stable position in the global competition of innovative drugs.
Reposted from: Pharmaceutical BD Club
$Biocytogen(688796.SH) $BIOCYTOGEN-B(02315.HK)
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
